Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Extracellular vesicles: emerging roles in the aged and neurodegenerative brain.

Frontiers in cellular neuroscience·2024
Same author

Microglia and TREM2.

Neuropharmacology·2024
Same author

Differential LRRK2 Signalling and Gene Expression in WT-LRRK2 and G2019S-LRRK2 Mouse Microglia Treated with Zymosan and MLi2.

Cells·2024
Same author

Differential LRRK2 signalling and gene expression in WT-LRRK2 and G2019S-LRRK2 mouse microglia treated with zymosan and MLi2.

bioRxiv : the preprint server for biology·2023
Same author

Differential Stimulation of Pluripotent Stem Cell-Derived Human Microglia Leads to Exosomal Proteomic Changes Affecting Neurons.

Cells·2021
Same author

Correction to: Wnt3a induces exosome secretion from primary cultured rat microglia.

BMC neuroscience·2020

Related Experiment Video

Updated: May 18, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Microglia, Alzheimer's disease, and complement.

Helen Crehan1, John Hardy, Jennifer Pocock

  • 1Department of Molecular Neurosciences, University College London Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, UK.

International Journal of Alzheimer'S Disease
|September 8, 2012
PubMed
Summary

Microglia, the brain's immune cells, interact with complement signaling in Alzheimer's disease (AD). Understanding this relationship is key to developing new AD therapies.

More Related Videos

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
06:43

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes

Published on: February 5, 2018

An Engulfment Assay: A Protocol to Assess Interactions Between CNS Phagocytes and Neurons
07:38

An Engulfment Assay: A Protocol to Assess Interactions Between CNS Phagocytes and Neurons

Published on: June 8, 2014

Related Experiment Videos

Last Updated: May 18, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
06:43

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes

Published on: February 5, 2018

An Engulfment Assay: A Protocol to Assess Interactions Between CNS Phagocytes and Neurons
07:38

An Engulfment Assay: A Protocol to Assess Interactions Between CNS Phagocytes and Neurons

Published on: June 8, 2014

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Microglia are brain immune cells implicated in neuronal loss and cognitive decline in Alzheimer's disease (AD).
  • Genome-wide association studies identify altered immune response and complement receptor 1 (CR1) gene variations as risk factors for late-onset AD.
  • Complement signaling plays a crucial role in neuroinflammation and AD pathogenesis.

Purpose of the Study:

  • To discuss the intersection of complement signaling and microglial responses in the context of Alzheimer's disease.
  • To explore how dysregulation of the complement cascade contributes to AD.
  • To investigate the impact of complement factors on microglial phenotypes in AD.

Main Methods:

  • Review and synthesis of existing literature on microglia, complement system, and Alzheimer's disease.
  • Analysis of findings from genome-wide association studies related to AD risk factors.
  • Discussion of the molecular mechanisms linking complement dysregulation to microglial function.

Main Results:

  • Dysregulation of the complement cascade (e.g., altered receptor expression, pathway activation, or factor imbalances) is implicated in AD.
  • Altered complement signaling can impair microglial phagocytosis of apoptotic cells and amyloid-beta peptides.
  • Complement factors influence microglia to adopt either protective or detrimental phenotypes in AD.

Conclusions:

  • The interplay between complement signaling and microglia is a significant factor in Alzheimer's disease.
  • Understanding how complement influences microglial phenotypes offers potential therapeutic targets for late-onset AD.
  • Further research is needed to harness this interaction for effective AD treatment.